Abu Dhabi is buying into advanced therapy, and research-ready provider groups can claim a place.

At the BIO International Convention in San Diego, the Department of Health Abu Dhabi signed a run of partnerships that move the emirate from collecting genomic data toward manufacturing therapies and treating patients. In late June 2026, M42 and the US gene-editing company Mammoth Biosciences, co-founded by Nobel laureate Jennifer Doudna, agreed to introduce Mammoth's lead candidate MB-111 into Abu Dhabi's clinical research ecosystem, qualify local sites for gene-editing trials, and establish GMP lipid-nanoparticle manufacturing. On 2 July 2026, Eli Lilly and the DOH signed an MOU to design an AI-enabled obesity and cardiometabolic care model and an Alzheimer's Disease Centre of Excellence. By 4 July the emirate reported around 22 partnerships from its US mission across genomics, AI and advanced therapeutics, with names including Boehringer Ingelheim, Novartis, and biologics manufacturing through Biosidus and Mubadala Bio.

The Emirati Genome Programme has sequenced more than 800,000 genomes toward a one-million target, among the largest single-population cohorts assembled anywhere. That cohort is why global biotech is signing in Abu Dhabi rather than treating it as a late-stage trial market. For a hospital group, the read-through is direct. The emirate is building the pieces of an advanced-therapy value chain, and each piece needs qualified trial sites, principal investigators and disease-specific centres to run on. Those roles are being allocated now, ahead of the manufacturing that follows.

A group that wants to host gene-editing or biologics trials has to show Good Clinical Practice systems, an ethics and institutional review process that clears protocols on a global sponsor's timeline, biobanking that meets international standards, and pharmacovigilance the EDE will accept. Cell and gene therapy adds cold-chain and handling requirements that most general hospitals do not yet meet. Sponsors like Mammoth and Lilly place trials where sites already run at that level. The gap between a well-run clinical hospital and a qualified advanced-therapy site is investment and process, and closing it is what earns the partnership.

Lilly's agreement stakes out obesity, cardiometabolic care and Alzheimer's. The gene-editing work targets rare and inherited disease, where the Emirati Genome data gives Abu Dhabi a genuine edge. A provider group cannot lead in all of these. The move is to pick the one or two areas where your case volume, clinical talent and data access let you credibly host a centre, then build toward the standard a global partner expects rather than waiting to be invited.

The EDE now controls marketing authorisation, GMP and pharmacovigilance, while the DOH governs facility licensing, change-of-control and research approvals in the emirate. Advanced-therapy trials and any local manufacturing sit squarely inside that framework. A group that engages the regulators early, and designs its trial-site and manufacturing ambitions to fit, moves faster than one that treats approvals as a later step. Alignment with national health strategy is itself part of the qualification.

The capital going into Abu Dhabi life sciences is chasing sites and capabilities that mostly do not yet exist at the required standard. A group that puts capital into GCP infrastructure, biobanking and a focused centre of excellence is building an asset that global sponsors and sovereign partners will pay to use. The window is open while the roles are unfilled. Once the first cohort of qualified sites and centres is set, the next tier competes for what is left.